I'm interested in how other organisations have managed a transition of
procedures and repertoires for biochemical markers of cardiac damage.
For example:
* Abandoning previously offered assays (Can it be done? Do you allow an
overlap period? Do you need a slow marker for the stoics who present
five days after chest pain?)
* Agreed TATs
* Managing the finances
* Quality issues with POCT assays
* Whether anyone has changed and then reverted to previous assays
Dr Jonathan Kay
University of Oxford
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|